Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KH domain-containing 3-like protein (KHDC3L) is a maternal effect protein expressed specifically in oocytes and early embryos. It is a core component of the subcortical maternal complex (SCMC), which is essential for early embryonic development and proper cell division after fertilization. KHDC3L plays a major role in regulation of DNA methylation and genomic imprinting, spindle assembly, chromosome segregation, and maintenance of genome stability in the zygote and early embryo. Mutations in KHDC3L lead to loss of function, causing recurrent biparental hydatidiform mole and recurrent pregnancy loss, and are associated with epigenetic and chromosomal abnormalities in early embryogenesis[1][3][5][6]. The protein contains an atypical KH RNA-binding domain and is unique to oocytes and pluripotent cells, underpinning early developmental competence but is not a conventional drug or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KH domain-containing 3-like, subcortical maternal complex member (KHDC3L).